FY2024 Earnings Forecast for Repare Therapeutics Inc. (NASDAQ:RPTX) Issued By Bloom Burton

Repare Therapeutics Inc. (NASDAQ:RPTX) – Equities research analysts at Bloom Burton increased their FY2024 earnings per share (EPS) estimates for shares of Repare Therapeutics in a research note issued to investors on Thursday, September 12th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of ($1.94) per share for the year, up from their prior estimate of ($2.92). The consensus estimate for Repare Therapeutics’ current full-year earnings is ($2.31) per share.

Other equities analysts also recently issued research reports about the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Repare Therapeutics in a research note on Wednesday, September 4th. Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $17.33.

Repare Therapeutics Stock Performance

RPTX stock opened at $3.29 on Monday. The company has a market capitalization of $139.66 million, a P/E ratio of -2.99 and a beta of 0.71. Repare Therapeutics has a 52-week low of $2.71 and a 52-week high of $13.85. The business has a 50-day simple moving average of $3.26 and a two-hundred day simple moving average of $3.69.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.03. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $4.02 million. Repare Therapeutics had a negative return on equity of 31.11% and a negative net margin of 99.76%.

Hedge Funds Weigh In On Repare Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of RPTX. XTX Topco Ltd purchased a new position in shares of Repare Therapeutics in the 2nd quarter worth approximately $110,000. Marshall Wace LLP purchased a new position in Repare Therapeutics in the second quarter valued at approximately $273,000. Jump Financial LLC purchased a new stake in Repare Therapeutics in the fourth quarter worth $289,000. Opaleye Management Inc. bought a new stake in shares of Repare Therapeutics in the first quarter valued at $318,000. Finally, Bank of Montreal Can lifted its position in shares of Repare Therapeutics by 5.4% during the 2nd quarter. Bank of Montreal Can now owns 110,935 shares of the company’s stock valued at $366,000 after buying an additional 5,673 shares during the last quarter. Hedge funds and other institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.